Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.

Duthie MS, Pereira L, Favila M, Hofmeyer KA, Reed SJ, Metangmo S, Townsend S, Laurance JD, Picone A, Misquith A, Hossain F, Ghosh P, Khan MAA, Guderian J, Bailor HR, Liang H, Vergara J, Oliveira F, Howard RF, Kamhawi S, Mondal D, Coler RN, Valenzuela JG, Reed SG.

NPJ Vaccines. 2017 Aug 21;2:23. doi: 10.1038/s41541-017-0025-5. eCollection 2017.

2.

Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites.

Hofmeyer KA, Duthie MS, Laurance JD, Favila MA, Van Hoeven N, Coler RN, Reed SG.

Clin Vaccine Immunol. 2016 Sep 6;23(9):785-94. doi: 10.1128/CVI.00251-16. Print 2016 Sep.

3.

Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis.

Duthie MS, Favila M, Hofmeyer KA, Tutterrow YL, Reed SJ, Laurance JD, Picone A, Guderian J, Bailor HR, Vallur AC, Liang H, Mohamath R, Vergara J, Howard RF, Coler RN, Reed SG.

Vaccine. 2016 May 27;34(25):2779-86. doi: 10.1016/j.vaccine.2016.04.067. Epub 2016 May 1.

4.

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG.

Clin Transl Immunology. 2015 Apr 10;4(4):e35. doi: 10.1038/cti.2015.6. eCollection 2015 Apr.

5.

Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.

Desbien AL, Reed SJ, Bailor HR, Dubois Cauwelaert N, Laurance JD, Orr MT, Fox CB, Carter D, Reed SG, Duthie MS.

Eur J Immunol. 2015 Feb;45(2):407-17. doi: 10.1002/eji.201444543. Epub 2014 Dec 3.

6.

Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.

Duthie MS, Coler RN, Laurance JD, Sampaio LH, Oliveira RM, Sousa AL, Stefani MM, Maeda Y, Matsuoka M, Makino M, Reed SG.

Infect Immun. 2014 Sep;82(9):3979-85. doi: 10.1128/IAI.02145-14. Epub 2014 Jul 14.

7.

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.

Orr MT, Kramer RM, Barnes L 5th, Dowling QM, Desbien AL, Beebe EA, Laurance JD, Fox CB, Reed SG, Coler RN, Vedvick TS.

J Control Release. 2014 Mar 10;177:20-6. doi: 10.1016/j.jconrel.2013.12.025. Epub 2013 Dec 29.

8.

Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses.

Desbien AL, Van Hoeven N, Reed SJ, Casey AC, Laurance JD, Baldwin SL, Duthie MS, Reed SG, Carter D.

Biotechniques. 2013 Jun;54(6):345-8. doi: 10.2144/000114041.

9.

Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.

Windish HP, Duthie MS, Misquith A, Ireton G, Lucas E, Laurance JD, Bailor RH, Coler RN, Reed SG.

Vaccine. 2011 Oct 13;29(44):7842-8. doi: 10.1016/j.vaccine.2011.07.094. Epub 2011 Aug 2. Erratum in: Vaccine. 2012 Dec 17;31(1):278. Misquith, Ayesha [added].

Supplemental Content

Loading ...
Support Center